Cargando…
Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702
We compared the efficacy and the safety of a carboplatin plus etoposide regimen (CE) vs split doses of cisplatin plus etoposide (SPE) in elderly or poor-risk patients with extensive disease small-cell lung cancer (ED-SCLC). Eligibility criteria included: untreated ED-SCLC; age ⩾70 and performance st...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360311/ https://www.ncbi.nlm.nih.gov/pubmed/17579629 http://dx.doi.org/10.1038/sj.bjc.6603810 |
_version_ | 1782153017367199744 |
---|---|
author | Okamoto, H Watanabe, K Kunikane, H Yokoyama, A Kudoh, S Asakawa, T Shibata, T Kunitoh, H Tamura, T Saijo, N |
author_facet | Okamoto, H Watanabe, K Kunikane, H Yokoyama, A Kudoh, S Asakawa, T Shibata, T Kunitoh, H Tamura, T Saijo, N |
author_sort | Okamoto, H |
collection | PubMed |
description | We compared the efficacy and the safety of a carboplatin plus etoposide regimen (CE) vs split doses of cisplatin plus etoposide (SPE) in elderly or poor-risk patients with extensive disease small-cell lung cancer (ED-SCLC). Eligibility criteria included: untreated ED-SCLC; age ⩾70 and performance status 0–2, or age <70 and PS 3. The CE arm received carboplatin area under the curve of five intravenously (IV) on day 1 and etoposide 80 mg m(−2) IV on days 1–3. The SPE arm received cisplatin 25 mg m(−2) IV on days 1–3 and etoposide 80 mg m(−2) IV on days 1–3. Both regimens were given with granulocyte colony-stimulating factor support in a 21–28 day cycle for four courses. A total of 220 patients were randomised. Median age was 74 years and 74% had a PS of 0 or 1. Major grade 3–4 toxicities were (%CE/%SPE): leucopenia 54/51, neutropenia 95/90, thrombocytopenia 56/16, infection 7/6. There was no significant difference (CE/SPE) in the response rate (73/73%) and overall survival (median 10.6/9.9 mo; P=0.54). Palliation scores were very similar between the arms. Although the SPE regimen is still considered to be the standard treatment in elderly or poor-risk patients with ED-SCLC, the CE regimen can be an alternative for this population considering the risk–benefit balance. |
format | Text |
id | pubmed-2360311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23603112009-09-10 Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 Okamoto, H Watanabe, K Kunikane, H Yokoyama, A Kudoh, S Asakawa, T Shibata, T Kunitoh, H Tamura, T Saijo, N Br J Cancer Clinical Study We compared the efficacy and the safety of a carboplatin plus etoposide regimen (CE) vs split doses of cisplatin plus etoposide (SPE) in elderly or poor-risk patients with extensive disease small-cell lung cancer (ED-SCLC). Eligibility criteria included: untreated ED-SCLC; age ⩾70 and performance status 0–2, or age <70 and PS 3. The CE arm received carboplatin area under the curve of five intravenously (IV) on day 1 and etoposide 80 mg m(−2) IV on days 1–3. The SPE arm received cisplatin 25 mg m(−2) IV on days 1–3 and etoposide 80 mg m(−2) IV on days 1–3. Both regimens were given with granulocyte colony-stimulating factor support in a 21–28 day cycle for four courses. A total of 220 patients were randomised. Median age was 74 years and 74% had a PS of 0 or 1. Major grade 3–4 toxicities were (%CE/%SPE): leucopenia 54/51, neutropenia 95/90, thrombocytopenia 56/16, infection 7/6. There was no significant difference (CE/SPE) in the response rate (73/73%) and overall survival (median 10.6/9.9 mo; P=0.54). Palliation scores were very similar between the arms. Although the SPE regimen is still considered to be the standard treatment in elderly or poor-risk patients with ED-SCLC, the CE regimen can be an alternative for this population considering the risk–benefit balance. Nature Publishing Group 2007-07-16 2007-06-19 /pmc/articles/PMC2360311/ /pubmed/17579629 http://dx.doi.org/10.1038/sj.bjc.6603810 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Okamoto, H Watanabe, K Kunikane, H Yokoyama, A Kudoh, S Asakawa, T Shibata, T Kunitoh, H Tamura, T Saijo, N Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 |
title | Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 |
title_full | Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 |
title_fullStr | Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 |
title_full_unstemmed | Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 |
title_short | Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 |
title_sort | randomised phase iii trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: jcog 9702 |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360311/ https://www.ncbi.nlm.nih.gov/pubmed/17579629 http://dx.doi.org/10.1038/sj.bjc.6603810 |
work_keys_str_mv | AT okamotoh randomisedphaseiiitrialofcarboplatinplusetoposidevssplitdosesofcisplatinplusetoposideinelderlyorpoorriskpatientswithextensivediseasesmallcelllungcancerjcog9702 AT watanabek randomisedphaseiiitrialofcarboplatinplusetoposidevssplitdosesofcisplatinplusetoposideinelderlyorpoorriskpatientswithextensivediseasesmallcelllungcancerjcog9702 AT kunikaneh randomisedphaseiiitrialofcarboplatinplusetoposidevssplitdosesofcisplatinplusetoposideinelderlyorpoorriskpatientswithextensivediseasesmallcelllungcancerjcog9702 AT yokoyamaa randomisedphaseiiitrialofcarboplatinplusetoposidevssplitdosesofcisplatinplusetoposideinelderlyorpoorriskpatientswithextensivediseasesmallcelllungcancerjcog9702 AT kudohs randomisedphaseiiitrialofcarboplatinplusetoposidevssplitdosesofcisplatinplusetoposideinelderlyorpoorriskpatientswithextensivediseasesmallcelllungcancerjcog9702 AT asakawat randomisedphaseiiitrialofcarboplatinplusetoposidevssplitdosesofcisplatinplusetoposideinelderlyorpoorriskpatientswithextensivediseasesmallcelllungcancerjcog9702 AT shibatat randomisedphaseiiitrialofcarboplatinplusetoposidevssplitdosesofcisplatinplusetoposideinelderlyorpoorriskpatientswithextensivediseasesmallcelllungcancerjcog9702 AT kunitohh randomisedphaseiiitrialofcarboplatinplusetoposidevssplitdosesofcisplatinplusetoposideinelderlyorpoorriskpatientswithextensivediseasesmallcelllungcancerjcog9702 AT tamurat randomisedphaseiiitrialofcarboplatinplusetoposidevssplitdosesofcisplatinplusetoposideinelderlyorpoorriskpatientswithextensivediseasesmallcelllungcancerjcog9702 AT saijon randomisedphaseiiitrialofcarboplatinplusetoposidevssplitdosesofcisplatinplusetoposideinelderlyorpoorriskpatientswithextensivediseasesmallcelllungcancerjcog9702 |